In the latest trading session, GlaxoSmithKline (GSK) closed at $41.27. This move was narrower than the S&P 500’s daily loss of 3.25%.
Coming into today, shares of the drug developer had lost 3.85% in the past month. In that same time, the Medical sector lost 1.96%, while the S&P 500 lost 5.62%.
GlaxoSmithKline will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0.68, down 13.92% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $11.12 billion, down 1.72% from the year-ago period. Yahoo analysts are expecting earnings of $3.18 per share and revenue of $48.8 billion. These totals would mark changes of +2.25% and +4.08%, respectively, from last year. It is also worth noting that GSK currently has a PEG ratio of 1.87. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company’s expected earnings growth rate into account. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.12 based on yesterday’s closing prices.
By supplying your email you agree to FP Markets privacy policy and receive future marketing materials from FP Markets. You can unsubscribe at any time.
Source - cache | Page ID - 829